All immunogenicity assessments present specific challenges. As a contract research organization (CRO), a major challenge we face is related to the lack of harmonization and standardization. Find out more in this editorial from a team at LGC (Cambridgeshire, UK).
Webinar live date: Thursday 10 January 2018 07:00 [PST] 10:00 [EST] 15:00 [GMT]. In this free panel discussion, our experts will provide insights into their own research with immunogenicity including the challenges they have had to overcome, key trends they have seen and their future outlook of the development of this field.
In this interview Alex Hawes (LGC; Cambridge, UK) discusses the topic of immunogenicity. She explains how she developed her first anti-drug antibody analytical method and the platforms LGC use in their immunogenicity sector.
SCIEX announces innovations in their ultra low-flow separation and accurate mass analysis, capillary electrophoresis–mass spectrometry (CESI-MS) technology and LGC announces investment plans in new GMP analytical capability.
This infographic presents key results from the large molecule quantification by LC–MS survey.
Rob Wheller, Principal Scientist from LGC (Fordham, UK), discusses his current research focuses; the advantages, disadvantages and challenges of the technologies he utilizes; and advice he would give to young, early-career scientists.
To date, almost all protein LC-MS/MS based bioanalysis has involved the use of trypsin to cleave biopharmaceuticals into manageable peptides for quantitation. In some cases, where trypsin does not generate useful peptide sequences, a different cleavage agent is required. Glu-C is an enzyme that is frequently used for protein characterisation, and cuts proteins on the C-terminal side of the aspartic and glutamic acid residues. These two molecules are acidic amino acids, whereas the ubiquitous trypsin cleaves at the basic residues (lysine and arginine), therefore making this an orthogonal cleavage enzyme.
Development of a UHPLC–MS/MS (SRM) method for the quantitation of endogenous glucagon and dosed GLP-1 from human plasma
In this research article, the authors discuss a LC–MS/MS method that offers a viable alternative to immunoassays for the quantitation of endogenous glucagon, dosed glucagon and/or dosed GLP-1.
Challenges and future predictions for oligonucleotide analysis: an interview with Hans-Peter Vornlocher
In this interview Hans-Peter Vornlocher, managing Director of Research at LGC Axolabs (Kulmbach, Germany), reflects on his career in the oligonucleotide field discussing the benefits and challenges of using oligonucleotides, his future predictions and what emerging technologies could aid analysis in the future.
LGC (Teddington, UK) have announced the combination of their Biosearch oligonucleotide reagent group with the newly acquired LINK technology, in the hope of enhancing oligonucleotide capabilities.